CoreMedic GmbH Stock

CoreMedic develops and manufactures devices to address the treatment of heart valve diseases. Lead product: ChordArt TMVr - System

Sign up today and learn more about CoreMedic GmbH Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About CoreMedic GmbH Stock

CoreMedic was initiated in 2012 as a spin-out of the Heart Center of University of Bern, Switzerland, in order to develop an innovative treatment concept for mitral valve regurgitation (MR). The initiators of CoreMedic had a simple but challenging idea: to combine the least invasive treatment option for MR, replacement of mitral chords, and the least invasive operational procedure into one new system: ChordArt. In 2017, the development of ChordArt had progressed towards first use in a human trial, enabling CoreMedic to attract institutional financing. The company moved to RIZ-innovation center at Radolfzell, Germany, located at Lake Constance close to the Swiss border within the leading medical technology cluster of Tuttlingen, Germany. Following successful conclusion of the first human trial of ChordArt in 2018, and two-year data confirming the powerful treatment effect of the ChordArt implant in patients with severe MR, CoreMedic GmbH is tirelessly working to make the ChordArt TMVr system available to patients. ​

Management

CEO

Thomas Bauer

CFO

Rainer Hoegg

CFO

Rainer Hoegg

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo